secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0000950170-24-107011
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Therapeutics receives Australian HREC approval to start Phase 1 SLE trial of CLN-978
--------------------------------------------------------------------------------

- HREC approval in Australia to initiate global Phase 1 trial of CLN-978 for systemic lupus erythematosus (SLE).
- CLN-978 is a CD19xCD3 bispecific T cell engager designed for off-the-shelf access and convenient dosing.
- SLE affects ~430,000 people globally; current treatments rarely induce treatment-free remission.
- Company also submitted IND to U.S. FDA for this study on September 16, 2024.
- Trial will assess safety, pharmacokinetics, and initial clinical activity in multiple countries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024107011/0000950170-24-107011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024107011/cgem-20240917.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-107011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer